Full Text
PMC17 SHOULD INDIRECT COSTS OF ILLNESS BE INCLUDED IN PHARMACOECONOMIC ANALYSIS- SURVEY AMONG POLISH DECISION MAKERS AND EXPERTS

Abstract

Authors

W Wrona D Golicki M Jakubczyk M Niewada M Czech T Macioch T Hermanowski

Back to Volume 12, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×